Clinical trials: H. Pylori Eradication Therapy, open to volunteers
HELICOBACTER PYLORI INFECTIONS, Helicobacter Infection
Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection
Helicobacter pylori is a Gram-negative, spiral-shaped bacterium that infects up to 50% of the world's population, residing in the gastric mucosa and using the mucus layer for protection from the stomach's high acidity.
- Conditions
- HELICOBACTER PYLORI INFECTIONS, Helicobacter Infection, Helicobacter Pylori Gastrointestinal Tract Infection, Helicobacter Pylori Infected Patients
- Trial name
- NCT07293910
- Testing
- Vonoparazan, Vitamin D, Probiotic
- Where
- Egypt
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- Tanta University
Helicobacter Pylori Eradication Rate
Optimization of Keverprazan-amoxicillin Dual Therapy for Eradicating Helicobacter Pylori Infection
Eradication of HP can significantly improve and reduce HP-related diseases. A 10-14 day quadruple regimen containing bismuth as first-line treatment, achieving an eradication rate of more than 85%.
- Trial name
- NCT06734260
- Testing
- Keverprazan Hydrochloride tablets + high dose amoxicillin, Keverprazan Hydrochloride tablets + low dose amoxicillin, Keverprazan Hydrochloride tablets + high dose amoxicillin（H-KA-10d）
- Where
- 4 sites in China
- Volunteers
- 477 people, healthy volunteers welcome
- Sponsor
- Eighth Affiliated Hospital, Sun Yat-sen University
Gastric Cancer, H Pylori Infection
H. Pylori Screen-and-treat Study in a Population of Young Adults
Gastric cancer remains a major challenge to public health on a global scale. H. pylori related cancer burden contributes to the largest proportion of cancer cases attributable to infections in Europe.
- Conditions
- Gastric Cancer, H Pylori Infection, H Pylori Eradication, H-pylori
- Trial name
- NCT06275204
- Testing
- Bismuth-based quadruple therapy, Levofloxacin-based quadruple therapy, Standard triple therapy
- Where
- 7 sites in Croatia, Ireland and 4 more
- Volunteers
- 6,800 people, healthy volunteers welcome
- Sponsor
- University of Latvia
Helicobacter Pylori Infections, Atrophic Gastritis
Multicentric Randomized Study of H. Pylori Eradication and Pepsinogen Testing for Prevention of Gastric Cancer Mortality
Currently no ideal preventive modalities are available for reducing gastric-cancer caused mortality in organized population-based application.
- Conditions
- Helicobacter Pylori Infections, Atrophic Gastritis, Gastric Cancer
- Trial name
- GISTAR (NCT02047994)
- Testing
- Triple therapy
- Where
- Latvia
- Volunteers
- 30,000 people, healthy volunteers welcome
- Sponsor
- International Agency for Research on Cancer
H. Pylori Gastrointestinal Disease, H.Pylori Infection
CURE-H. Pylori: A Trial on the Combination of Anti-Ulcerants and Levofloxacin-Based Therapy for Helicobacter Pylori Eradication
This study, titled CURE-H. Pylori, is a three-arm, parallel-group, open-label, randomized controlled trial designed to evaluate the effectiveness of Dexlansoprazole, Lansoprazole, and Vonoprazan in combination with Levofloxacin…
- Conditions
- H. Pylori Gastrointestinal Disease, H.Pylori Infection, H.Pylori Eradication Rate
- Trial name
- CURE-H Pylori (NCT07344506)
- Testing
- Arm 1: Dexlansoprazole + Levofloxacin-Based Triple Therapy, Arm 2: Lansoprazole + Levofloxacin-Based Triple Therapy, Arm 3: Vonoprazan + Levofloxacin-Based Triple Therapy
- Where
- Pakistan
- Volunteers
- 942 people, healthy volunteers welcome
- Sponsor
- Dow University of Health Sciences
Helicobacter Pylori Infection
Tegoprazan-containing Sequential for H. Pylori
As H. pylori eradication, the investigators prepared a randomized controlled clinical trial whether tegoprazan-containing 10-day sequential treatment was effective compared to conventional PPI-containing 10-day sequential…
- Trial name
- NCT06382493
- Testing
- Tegoprazan-containing sequential H. pylori eradication therapy, Esomeprazole-containing sequential H. pylori eradication therapy
- Where
- South Korea
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Seoul National University Bundang Hospital
Helicobacter Infection
The Efficacy of the 7 Days Tailored Therapy as the 1st Eradication of H. Pylori Infection
To compare the eradication success rate between 10-days sequential therapy and 7-days tailored therapy based on H. pylori culture and antimicrobial susceptibility testing.
- Trial name
- NCT02373280
- Testing
- 10 day sequential therapy (Esomeprazole, amoxicillin, clarithromycin, metronidazole), 7 day tailored PPI triple therapy (clarithromycin-containing triple therapy), 7 day moxifloxacin based triple therapy [Esomeprazole, Moxifloxacin, Amoxicillin]
- Where
- South Korea
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Seoul National University Bundang Hospital